Complete remission of Hodgkin Lymphoma after a concurrent infection with COVID-19: systematic review and meta-analysis
Through December 2019, novel coronavirus (SARS-CoV-2) pneumonia (COVID-19) was reported in Wuhan and has since rapidly spread throughout China. Hodgkin lymphoma represents a heterogeneous hematological malignancy, which is characterized by immunosuppression. There are no clearly defined risk factors...
Main Author: | Nasser ghaly yousif |
---|---|
Format: | Article |
Language: | English |
Published: |
Al Muthanna University
2022-09-01
|
Series: | Muthanna Medical Journal |
Subjects: | |
Online Access: | https://muthmj.mu.edu.iq/wp-content/uploads/2022/07/Complete-remission-of-Hodgkin-Lymphoma-after-a-concurrent-infection-with-COVID-19-systematic-review-and-meta-analysis.pdf |
Similar Items
-
Inferior survival and frequent hepatic dysfunction in non-Hodgkin’s lymphoma patients with HBV infection: a systematic review and meta-analysis
by: Min-Yue Zhang, et al.
Published: (2022-01-01) -
Long‐term complete remission and peripheral biomarkers in Hodgkin lymphoma patients after decitabine‐plus‐camrelizumab epi‐immunotherapy and treatment cessation
by: Chunmeng Wang, et al.
Published: (2023-12-01) -
A case of complete remission of Hodgkin lymphoma confirmed histopathologically by neck dissection
by: Yu Ohashi, et al.
Published: (2023-08-01) -
How I Follow Hodgkin Lymphoma in First Complete (Metabolic) Remission?
by: Vibor Milunović
Published: (2024-02-01) -
Treatment outcomes in classic Hodgkin lymphoma: 5‐year update from the Brazilian Hodgkin Lymphoma Registry
by: Irene Biasoli, et al.
Published: (2023-11-01)